Vera Therapeutics, Inc.

What they do

Vera Therapeutics develops and commercializes therapies for autoimmune diseases, starting with kidney conditions. Its lead product, TRUTAKNA (atacicept-vymj), was granted accelerated FDA approval on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy (IgAN). The company also holds rights to MAU868 (a BK virus antibody, Phase 2 completed) and VT-109 (a preclinical BAFF/APRIL inhibitor). It relies on third-party manufacturers and has not yet recorded significant product revenue.

Revenue drivers

• TRUTAKNA (atacicept-vymj) — The only approved product; launched commercially in the U.S. in Q3 2026, with limited revenue expected in Q3 2026. Priced as a once-weekly autoinjector; no sales figures disclosed yet.
• TRU SUPPORT patient program — Market access program limiting out-of-pocket costs to $0 for eligible commercially insured patients, intended to support uptake of TRUTAKNA.

Recent performance

For Q2 2026, Vera reported financial results on August 10, 2026, highlighting the accelerated approval and launch of TRUTAKNA. The company has no product revenue to date; net losses have grown from $152.1M in 2024 to $299.6M in 2025. Operating cash flow was -$241.1M in 2025. As of June 30, 2026, cash and equivalents were $48.9M, total assets $533.0M, and long-term debt $75.2M.

Strategy

Management is focused on executing a U.S. specialty launch of TRUTAKNA with an experienced commercial team. It plans to pursue full FDA approval via an sBLA expected in Q4 2026, following ORIGIN 3 final efficacy data in Q3 2026. Beyond IgAN, the company is evaluating atacicept in other autoimmune kidney diseases (pMN, FSGS, MCD) and potential future indications. It continues to advance the ORIGIN 3 program and a dose-range finding study, and holds rights to MAU868 and VT-109 for pipeline expansion.

Risks

• No commercial revenue history — Vera has never generated product revenue and only expects limited sales in Q3 2026, making profitability uncertain.
• Dependence on TRUTAKNA approval and launch — Full FDA approval hinges on ORIGIN 3 final efficacy data and sBLA, with commercial success dependent on market acceptance.
• Cash burn and funding need — With only $48.9M cash and a $241.1M annual operating cash outflow, the company will likely need additional capital.
• Clinical and regulatory execution risk — Delays in trial results, sBLA submission, or future indication development could materially affect the business.

Outlook

Management expects ORIGIN 3 final efficacy results in Q3 2026, with an sBLA submission in Q4 2026 and potential full FDA approval in 2027. Additional PIONEER Phase 2 results are expected in Q4 2026. The company is focused on a successful U.S. launch of TRUTAKNA and advancing its pipeline.